INDIVIOR PLC/S (OTCMKTS:INVVY) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday.
According to Zacks, “Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States. “
A number of other equities analysts have also commented on the stock. ValuEngine lowered shares of INDIVIOR PLC/S from a “hold” rating to a “sell” rating in a research report on Saturday, July 28th. Citigroup restated a “neutral” rating on shares of INDIVIOR PLC/S in a research report on Thursday, May 31st.
INDIVIOR PLC/S (OTCMKTS:INVVY) last released its quarterly earnings results on Thursday, July 26th. The company reported $0.45 EPS for the quarter. The firm had revenue of $268.00 million during the quarter. equities research analysts predict that INDIVIOR PLC/S will post 1.74 EPS for the current year.
About INDIVIOR PLC/S
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, overdose rescue, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for INDIVIOR PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INDIVIOR PLC/S and related companies with MarketBeat.com's FREE daily email newsletter.